Researcher.Life Logo

PharmacoEconomics - Open : Impact Factor & More

eISSN: 2509-4254pISSN: 2509-4262
JournalOpen Access

Key Metrics

CiteScore
2.9
H-Index
17
SJR
Q2Pharmacology
SNIP
0.78
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on PharmacoEconomics - Open

PharmacoEconomics - Open Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher SPRINGER INT PUBL AG
Language English
Frequency Quarterly
Article Processing ChargesEUR 2790 | USD 3490 | GBP 2390
Publication Time8
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyQuarterly
Publication Start Year2017
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 8
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY-NC
OA statementVisit website
View less

Planning to publish in PharmacoEconomics - Open ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in PharmacoEconomics - Open

Value of Emerging and Existing Pre-prophylaxis and Therapeutic Options for COVID-19 in Transplant Recipients: A Systematic Review of Economic Evaluations.
  • 29 Jan 2026
  • PharmacoEconomics - open
Assessing the Expected Costs of Continuous Remote Monitoring for Post-Discharge Home Use and the Readmission Reduction Required to Achieve Cost Neutrality.
  • 27 Jan 2026
  • PharmacoEconomics - open
A Cost-Analysis and Micro-Costing Study of the Man Van Project: Comparing Prostate-Specific Antigen Testing Via a Nurse-Led Mobile Service with Primary Care.
  • 23 Jan 2026
  • PharmacoEconomics - open
Content Validity of Two Generic Preference-Based Measures in Retinitis Pigmentosa, Including X-Linked Retinitis Pigmentosa.
  • 23 Jan 2026
  • PharmacoEconomics - open
Incremental Disease Burden (Healthcare Costs and Resources) of Duchenne Muscular Dystrophy in the US: A Matched Cohort Analysis.
  • 20 Jan 2026
  • PharmacoEconomics - open
Cost-Effectiveness of RefluxStop Versus Nissen Fundoplication and Proton Pump Inhibitors for Refractory Gastroesophageal Reflux Disease: A Spanish Healthcare Perspective.
  • 14 Jan 2026
  • PharmacoEconomics - open
Value of Emerging and Existing Pre-prophylaxis and Therapeutic Options for COVID-19 in Transplant Recipients: A Systematic Review of Economic Evaluations.
  • 29 Jan 2026
  • PharmacoEconomics - open
Assessing the Expected Costs of Continuous Remote Monitoring for Post-Discharge Home Use and the Readmission Reduction Required to Achieve Cost Neutrality.
  • 27 Jan 2026
  • PharmacoEconomics - open
A Cost-Analysis and Micro-Costing Study of the Man Van Project: Comparing Prostate-Specific Antigen Testing Via a Nurse-Led Mobile Service with Primary Care.
  • 23 Jan 2026
  • PharmacoEconomics - open
Content Validity of Two Generic Preference-Based Measures in Retinitis Pigmentosa, Including X-Linked Retinitis Pigmentosa.
  • 23 Jan 2026
  • PharmacoEconomics - open
Incremental Disease Burden (Healthcare Costs and Resources) of Duchenne Muscular Dystrophy in the US: A Matched Cohort Analysis.
  • 20 Jan 2026
  • PharmacoEconomics - open
Cost-Effectiveness of RefluxStop Versus Nissen Fundoplication and Proton Pump Inhibitors for Refractory Gastroesophageal Reflux Disease: A Spanish Healthcare Perspective.
  • 14 Jan 2026
  • PharmacoEconomics - open

FAQs on PharmacoEconomics - Open